Companies
Global Bioenergies
French developer of a direct-fermentation route to bio-isobutene (a renewable C4 olefin), proven at demo scale in Pomacle. In receivership (redressement judiciaire) since 29 September 2025, with the takeover-bid hearing adjourned in November 2025 under an explicit liquidation risk and its Euronext Growth listing (ALGBE) suspended — treat as unavailable as a supplier pending the outcome.
- Country
- France
- Ticker
- EPA:ALGBE
Coverage
| CN | EU | US | |
|---|---|---|---|
| platform-chemicals | ✓ | ✓ | ✓ |
Regulatorsepareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | IPO in 2011 raised EUR 6.6 million; 2019 public capital increase; 2021 capital increase of EUR 14.5 million; 2023 rights issue of EUR 5.6 million; various non-dilutive public funding including EUR 7.3 million received in 2023 | biobase.whitefordresearch.com |
| Capacity | 100 tonnes of isobutene per year at the Pomacle unit as of 2022 | globenewswire.com |
| Certification | Technology certified by ASTM for sustainable aviation fuel as of 2023 | marketscreener.com · biobase.whitefordresearch.com · globenewswire.com |
| Regulatory approval | Isonaturane® 12 ingredients cleared regulatory hurdles for use in cosmetics as of 2022 | marketscreener.com · globenewswire.com |
| Production site | Pomacle, France (unit for isobutene production) | biobase.whitefordresearch.com · bioenergyinternational.com · globenewswire.com |
| Headcount | 48.8 employees on average in 2022 medium confidence | renewable-carbon.eu |
| Revenue | EUR 700,000 in 2022 | renewable-carbon.eu |
Independent sources: biobase.whitefordresearch.com · bioenergyinternational.com · globenewswire.com · marketscreener.com · renewable-carbon.eu
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic butanol, isobutanol and bio-C4 platforms | platform-chemicals | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.